The inhibition of chymotrypsin A4 with a homologous series of chloromethyl ketone reagents
The inactivation of chymotrypsin A4 (CHT-A4) by a homologous phenylalkyl series of bifunctional reagents, viz. phenyl chloromethyl ketone (PCK), benzyl chloromethyl ketone (BCK), and β-phenylethyl chloromethyl ketone (βPECK) (C6H5 [CH2]n COCH2Cl where n = 0, 1, or 2), has been investigated. The inactivation of CHT-A4 by PCK has been shown to be essentially pH independent whereas inactivation by BCK and βPECK appears to be dependent on a basic group of pK 6.0–6.3. PCK has been shown to inhibit CHT-A4 by virtue of the complete S-alkylation of methionine-192. BCK and βPECK, on the other hand, inactivate CHT-A4 through a combination of partial S-alkylation of methionine-192 (0.2 and 0.3 residue, respectively) and partial alkylation of histidine-57 (0.2 and 0.4 residue, respectively). Identification of the particular residue alkylated was obtained through the isolation and analysis of alkylated and oxidized peptic peptides obtained from the alkylated CHT-A4 by the diagonal peptide ionophoresis technique.The initial site of alkylation of BCK and βPECK on the imidazole ring of histidine-57 has not been identified. However, a unique histidine derivative has been isolated from the acid hydrolysate of oxidized histidine-57 peptide from CHT-A4–βPECK and is suggested to be 2(or 4)-hydroxymethylhistidine.On the basis of the present studies on the phenylalkyl series and on studies reported earlier on a phenylalkylamido halomethyl ketone series of bifunctional reagents which alkylates only methionine in CHT-A4, it has been suggested that alkylation of histidine by members of the phenylalkyl series is primarily a result of binding to the hydrophobic binding site of CHT-A4 rather than binding to the acylamido binding site as is suggested to be the case for the phenylalkylamido series.